title: MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma.
abstract: One of the best prognostic predictors for patients with epithelial ovarian cancer is the Federation of Obstetrics and Gynecology (FIGO) stage at diagnosis. Advanced-stage ovarian serous carcinoma (OSC) generally have poor prognosis. The goal of this study is to develop and validate a miRNA expression profile that can differentiate the OSC at early and advanced stages and study its correlation with the prognosis of OSC. To identify a unique microRNA (miRNA) pattern associated with the progression of OSC at early and advanced stages, a miRNA microarray was performed using Chinese tumor bank specimens of patients with OSC stage I or III in a retrospective analysis. The expression of four dysregulated miRNAs was validated using quantitative real-time polymerase chain reaction (qRT-PCR) in an external cohort of 51 cases of OSC samples at stages I and III. Kaplan-Meier analysis was performed to analyze the correlation between the expression of some miRNAs and prognosis. Of the 768 miRNAs analyzed in the microarray, 26 miRNAs were significantly either up- or downregulated, with at least a 2-fold difference, in OSC stage I compared with stage III. The qRT-PCR results showed that miR-510, miR-509-5p, and miR-508-3p were significantly downregulated and that miR-483-5p was upregulated in stage III OSC compared with stage I, which was consistent with the microarray results. Kaplan-Meier analysis showed low miR-510 expression, low miR-509-5p expression, and advanced FIGO stage, and chemotherapy resistance were significantly associated with poorer overall survival (P < 0.05). Our results suggest that miRNAs may play a role in the progression of OSC, and miR-510 and miR-509-5p may be considered novel-candidate clinical biomarkers for predicting OSC outcome.
authors.affiliation: Department of Histology and Embryology, Dalian Medical University, No 9 LvShun South Road-W, 116044, Dalian, China.
authors.forename: Xiaotang
authors.initials: X
authors.lastname: Yu
authors.forename: Xinchen
authors.initials: X
authors.lastname: Zhang
authors.forename: Tie
authors.initials: T
authors.lastname: Bi
authors.forename: Yanfang
authors.initials: Y
authors.lastname: Ding
authors.forename: Jinyao
authors.initials: J
authors.lastname: Zhao
authors.forename: Chang
authors.initials: C
authors.lastname: Wang
authors.forename: Tingting
authors.initials: T
authors.lastname: Jia
authors.forename: Dan
authors.initials: D
authors.lastname: Han
authors.forename: Gordon
authors.initials: G
authors.lastname: Guo
authors.forename: Bo
authors.initials: B
authors.lastname: Wang
authors.forename: Jiyong
authors.initials: J
authors.lastname: Jiang
authors.forename: Shiying
authors.initials: S
authors.lastname: Cui
mesh_terms: D000328:Adult; D000368:Aged; D016000:Cluster Analysis; D018284:Cystadenocarcinoma, Serous / Q000235:genetics* / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009367:Neoplasm Staging; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology; D011379:Prognosis; D060888:Real-Time Polymerase Chain Reaction; D059467:Transcriptome
chemical_list: D035683:MicroRNAs